Association Between the Sit-To-Stand Test and the Prognosis of Patients With Heart Failure
Recruiting
Observational Study
Heart FailureHeart Failure NYHA Class IVHeart Failure; With DecompensationHeart Failure NYHA Class IIIHeart Failure NYHA Class II
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
68 (estimated)
Sponsor
Centro Universitário Augusto Motta · Other
Who this trial is looking for
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Introduction: Heart failure (HF), among cardiovascular diseases, is the disease that has been increasing its incidence and prevalence the most in recent years in the world population, due to the aging of the population. In addition, HF is the most frequent hospital diagnosis in the elderly, and is the main cause of hospitalization, with significant expenditure in public and private health care wor…
Introduction: Heart failure (HF), among cardiovascular diseases, is the disease that has been increasing its incidence and prevalence the most in recent years in the world population, due to the aging of the population. In addition, HF is the most frequent hospital diagnosis in the elderly, and is the main cause of hospitalization, with significant expenditure in public and private health care worldwide. Some functional tests have been used to predict the prognosis in patients with HF, however, the use of the 1-minute sit-to-stand test (SST1) to predict prognosis in HF has little scientific evidence, due to the lack of studies found in the literature for this population. Thus, the present study aims to evaluate the association between SST1 at discharge from the Cardio Intensive Care Unit (ICU) and the clinical outcome after 90 days in patients hospitalized for decompensated heart failure (DHF). Methods: This is a prospective cohort study analyzing the association between performance on the TSL1 and clinical outcome in patients hospitalized for DHF from June 2025 to October 2025. Sociodemographic, family, social, and clinical data will be collected from the participants, after which the TSL1 will be performed. The outcome of death and hospital readmission within 90 days after discharge from the ICU will be identified through telephone contact, which will be carried out by the researcher. Expected results: It is expected that from the results of this study it will be possible to understand whether performance on the TSL1 predicts clinical outcome for patients hospitalized for DHF and that it will even be possible to determine a cutoff point capable of predicting the outcomes of interest.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Patients diagnosed with CDI;
* Over 18 years of age;
* With an Intensive Care Unit Mobility Scale (IMS) \> 4 at discharge from the ICU;
* Able to sit and stand up from a chair without support from the upper limbs (ULs) will be included in the study.
Exclusion Criteria:
* Pat…
Inclusion Criteria:
* Patients diagnosed with CDI;
* Over 18 years of age;
* With an Intensive Care Unit Mobility Scale (IMS) \> 4 at discharge from the ICU;
* Able to sit and stand up from a chair without support from the upper limbs (ULs) will be included in the study.
Exclusion Criteria:
* Patients with cognitive alterations;
* Level of consciousness, with \[RASS (Richmond Agitation and Sedation Scale) \>+1 or \<-2 and Glasgow \<13 (Coma Scale)\], neurological and orthopedic, which compromise the understanding and performance of the assessment will be excluded;
* Patients with advanced invasive ventilatory and circulatory support or in cardiogenic shock.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.